More info:

• Popular Products

  Viagra Cialis Viagra Professional Cialis Professional Amoxil Prednisolone Lasix Propecia Levitra

• Androxal: Restoring Endogenous Testosterone for Hypogonadism - An Evidence-Based Review

  Product Description: Androxal is the brand name for enclomiphene citrate, a selective estrogen receptor modulator (SERM) administered orally. It is distinct from its isomer, zuclomiphene, which is found in the commonly prescribed fertility drug clomiphene citrate. Androxal acts centrally at the hypothalamus to stimulate the body’s own production of testosterone and sperm, positioning it as a potential therapeutic alternative to exogenous testosterone replacement therapy (TRT) for men with specific endocrine disorders.

• Arimidex (Anastrozole): Effective Estrogen Suppression for Breast Cancer Therapy - Evidence-Based Review

  Product Description: Arimidex is the brand name for the pharmaceutical compound anastrozole. It is classified as a non-steroidal aromatase inhibitor and is available as a prescription medication in tablet form. It is not a dietary supplement or an over-the-counter medical device. Its primary and approved use is in the field of oncology, specifically for the treatment of hormone receptor-positive breast cancer in postmenopausal women. It functions by dramatically reducing the production of estrogen in the body, which can fuel the growth of certain types of breast cancer cells.

• Aromasin

  Let me start by describing what we’re really talking about here, because the name “Aromasin” gets thrown around a lot in oncology circles, but its impact is deeply personal for every patient who takes it. In essence, Aromasin is the brand name for exemestane, a steroidal aromatase inactivator. It’s not a supplement; it’s a potent, prescription-only oral medication classified as a hormonal therapy. We use it predominantly in postmenopausal women with estrogen receptor-positive (ER+) breast cancer, both in the adjuvant setting to prevent recurrence after initial treatment and in the metastatic setting to control advanced disease.

• Chloroquine

  Chloroquine: A comprehensive review of its mechanisms, established uses, and evolving role in medicine. This evidence-based monograph covers its pharmacology, approved indications, safety profile, and the controversies surrounding its repurposing. Learn about the critical clinical evidence and appropriate therapeutic applications. Let’s talk about chloroquine. If you’re reading this, you’ve likely encountered it in a whirlwind of headlines, or perhaps you’re an old hand who remembers it from the malaria prophylaxis days.

• Enclomisign: A Next-Generation Oral SERD for ER+ Breast Cancer - Evidence-Based Review

  Product Description Enclomisign is a novel, non-hormonal, orally administered small molecule therapeutic agent currently under investigation as a selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor-positive (ER+) breast cancer. It is designed to overcome limitations of current endocrine therapies, such as acquired resistance to selective estrogen receptor modulators (SERMs) like tamoxifen and degradation-resistant mutations in the estrogen receptor. Unlike traditional SERDs that are often large molecules with poor oral bioavailability (e.

• Eulexin (Flutamide): Terapia di Blocco Androgenico Completo nel Carcinoma Prostatico - Monografia Evidence-Based

  Product Description: Eulexin, nome commerciale del principio attivo flutamide, è un farmaco antiandrogeno non steroideo appartenente alla classe degli antagonisti del recettore degli androgeni. Viene utilizzato esclusivamente in ambito oncologico, in combinazione con analoghi dell’ormone di rilascio delle gonadotropine (GnRH), per il trattamento del carcinoma prostatico avanzato ormono-sensibile (metastatico o non metastatico). Il suo meccanismo d’azione si basa sull’inibizione competitiva del legame del diidrotestosterone (DHT) e del testosterone ai loro recettori citoplasmatici nelle cellule target, incluso il tessuto prostatico neoplastico.

• Evista

  Evista (Raloxifene): Prevenzione dell’Osteoporosi e Riduzione del Rischio di Carcinoma Mammario - Monografia Basata sull’Evidenza Prima di entrare nei dettagli della monografia, è fondamentale definire cos’è Evista. Il principio attivo è il cloridrato di raloxifene, commercializzato da Eli Lilly. Non è un integratore alimentare, ma un farmaco soggetto a prescrizione medica, classificato come modulatore selettivo del recettore degli estrogeni (SERM). La sua particolarità, e la ragione del suo sviluppo, risiede nella capacità di agire come agonista o antagonista degli estrogeni in modo tessuto-specifico.

• Evista: Bone Preservation and Breast Cancer Risk Reduction in Postmenopausal Women - Evidence-Based Review

  Product Description: Evista is the trade name for raloxifene hydrochloride, a selective estrogen receptor modulator (SERM) approved by the FDA and other global regulatory bodies. It is not a dietary supplement or a medical device in the traditional sense, but rather a prescription medication. It is primarily indicated for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk for invasive breast cancer.

• Femalefil

  Product Description Femalefil is a class IIa medical device, specifically a vaginal dilator system, designed for the non-hormonal, physical management of genitourinary syndrome of menopause (GSM), vaginal stenosis, and dyspareunia. It is not a dietary supplement. The system employs a proprietary, graduated bio-conforming polymer technology to facilitate controlled, progressive tissue dilation and remodeling. Its primary mechanism is mechanical, promoting increased elasticity, vascular flow, and epithelial integrity through consistent, patient-guided use. Think of it less as a simple “stretcher” and more as a physiotherapy tool for the vaginal canal, addressing the structural and functional deficits that occur with hypoestrogenism, post-radiation therapy, or post-surgical scarring.